Amgen Future Growth
Future criteria checks 3/6
Amgen is forecast to grow earnings and revenue by 19.1% and 2.4% per annum respectively. EPS is expected to grow by 19.6% per annum. Return on equity is forecast to be 206.6% in 3 years.
Key information
19.1%
Earnings growth rate
19.6%
EPS growth rate
| Biotechs earnings growth | 27.4% |
| Revenue growth rate | 2.4% |
| Future return on equity | 206.6% |
| Analyst coverage | Good |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02
Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Recent updates
Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 34,915 | 7,607 | 13,538 | 13,878 | 23 |
| 12/31/2025 | 34,302 | 6,529 | 12,291 | 13,046 | 27 |
| 12/31/2024 | 33,183 | 4,794 | 11,990 | 12,964 | 26 |
| 9/30/2024 | 32,534 | 4,230 | 6,283 | 7,257 | N/A |
| 6/30/2024 | 30,934 | 3,130 | 5,481 | 6,446 | N/A |
| 3/31/2024 | 29,532 | 3,763 | 7,098 | 8,096 | N/A |
| 12/31/2023 | 28,190 | 6,717 | 7,359 | 8,471 | N/A |
| 9/30/2023 | 26,833 | 7,566 | 9,379 | 10,582 | N/A |
| 6/30/2023 | 26,582 | 7,979 | 9,685 | 10,800 | N/A |
| 3/31/2023 | 26,190 | 7,917 | 7,531 | 8,621 | N/A |
| 12/31/2022 | 26,323 | 6,552 | 8,785 | 9,721 | N/A |
| 9/30/2022 | 26,330 | 6,835 | 8,997 | 9,880 | N/A |
| 6/30/2022 | 26,384 | 6,576 | 8,355 | 9,320 | N/A |
| 3/31/2022 | 26,316 | 5,723 | 8,417 | 9,321 | N/A |
| 12/31/2021 | 25,979 | 5,893 | 8,381 | 9,261 | N/A |
| 9/30/2021 | 25,767 | 5,609 | 7,840 | 8,606 | N/A |
| 6/30/2021 | 25,484 | 5,746 | 8,897 | 9,556 | N/A |
| 3/31/2021 | 25,164 | 7,085 | 9,835 | 10,467 | N/A |
| 12/31/2020 | 25,424 | 7,264 | 9,889 | 10,497 | N/A |
| 9/30/2020 | 24,987 | 7,352 | 10,235 | 10,858 | N/A |
| 6/30/2020 | 24,301 | 7,299 | 10,209 | 10,867 | N/A |
| 3/31/2020 | 23,966 | 7,675 | 8,795 | 9,439 | N/A |
| 12/31/2019 | 23,362 | 7,842 | 8,532 | 9,150 | N/A |
| 9/30/2019 | 23,395 | 8,067 | 9,175 | 9,830 | N/A |
| 6/30/2019 | 23,562 | 7,958 | 9,070 | 9,726 | N/A |
| 3/31/2019 | 23,750 | 8,075 | 9,715 | 10,414 | N/A |
| 12/31/2018 | 23,747 | 8,394 | 10,558 | 11,296 | N/A |
| 9/30/2018 | 23,319 | 2,202 | 10,448 | 11,114 | N/A |
| 6/30/2018 | 23,188 | 2,364 | N/A | 11,295 | N/A |
| 3/31/2018 | 22,939 | 2,219 | N/A | 11,519 | N/A |
| 12/31/2017 | 22,849 | 1,979 | N/A | 11,177 | N/A |
| 9/30/2017 | 23,012 | 8,178 | N/A | 11,265 | N/A |
| 6/30/2017 | 23,050 | 8,174 | N/A | 10,473 | N/A |
| 3/31/2017 | 22,928 | 7,893 | N/A | 10,824 | N/A |
| 12/31/2016 | 22,991 | 7,722 | N/A | 10,354 | N/A |
| 9/30/2016 | 22,562 | 7,587 | N/A | 9,327 | N/A |
| 6/30/2016 | 22,474 | 7,433 | N/A | 9,557 | N/A |
| 3/31/2016 | 22,156 | 7,216 | N/A | 10,164 | N/A |
| 12/31/2015 | 21,662 | 6,939 | N/A | 9,731 | N/A |
| 9/30/2015 | 21,457 | 6,433 | N/A | 10,103 | N/A |
| 6/30/2015 | 20,765 | 5,814 | N/A | 9,952 | N/A |
| 3/31/2015 | 20,575 | 5,708 | N/A | 8,895 | N/A |
| 12/31/2014 | 20,063 | 5,158 | N/A | 8,952 | N/A |
| 9/30/2014 | 19,743 | 4,885 | N/A | 7,945 | N/A |
| 6/30/2014 | 19,460 | 5,009 | N/A | 7,011 | N/A |
| 3/31/2014 | 18,959 | 4,720 | N/A | 6,384 | N/A |
| 12/31/2013 | 18,676 | 5,081 | N/A | 6,291 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMGN's forecast earnings growth (19.1% per year) is above the savings rate (2.6%).
Earnings vs Market: AMGN's earnings (19.1% per year) are forecast to grow faster than the US market (15.5% per year).
High Growth Earnings: AMGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMGN's revenue (2.4% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: AMGN's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMGN's Return on Equity is forecast to be very high in 3 years time (206.6%).